UPDATE: Goldman Sachs Downgrades Baxter International (BAX) to Sell

Goldman Sachs analyst Amit Hazan downgraded Baxter International (NYSE: BAX) from Neutral to Sell with a price target of $77.00 (from $88.00).

The analyst comments "As we think about the relative positioning of LC Medtech, we see BAX as the (1) more exposed to macro headwinds, (2) one of the least exposed to the developing COVID-19 recovery tailwinds, while also (3) holding some concerns over the base business. In short, we expect these incremental headwinds and lack of tailwinds are still not fully reflected in estimates."

For an analyst ratings summary and ratings history on Baxter International click here. For more ratings news on Baxter International click here.

Shares of Baxter International closed at $78.58 yesterday.

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Goldman Sachs Downgrades Shanghai Jahwa United (600315:CH) to Neutral